Focused On-demand Library for Endonuclease V

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q8N8Q3

UPID:
ENDOV_HUMAN

ALTERNATIVE NAMES:
Inosine-specific endoribonuclease

ALTERNATIVE UPACC:
Q8N8Q3; I3L3S4; Q6P2G2; Q86X99; Q8NAK0

BACKGROUND:
The protein Endonuclease V, alternatively known as Inosine-specific endoribonuclease, is distinguished by its specificity for inosine-containing RNAs. It cleaves these RNAs at a precise location, indicating a critical role in RNA editing and turnover. The enzyme's activity on both single and double-stranded RNAs, with a marked preference for the former, underscores its importance in cellular RNA dynamics, including the processing of edited RNAs.

THERAPEUTIC SIGNIFICANCE:
The exploration of Endonuclease V's function presents a promising avenue for drug discovery. Given its unique enzymatic activity and probable role in antiviral defense by targeting hyperedited viral genomes, it stands as a potential target for developing novel antiviral therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.